Iggenix, Inc

Iggenix, Inc company information, Employees & Contact Information

Updated June 2026

Quick answer

Iggenix, Inc is a Biotechnology Research company and founded in 2019. It has approximately 12 employees on record. Contact data was last refreshed in June 2026. Find Iggenix, Inc's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

IgGenix is a clinical-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

Company Details

Employees
12
Founded
2019
Address
South San Francisco, Ca 94080, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Milpitas.
HQ
South San Francisco, CA
Looking for a particular Iggenix, Inc employee's phone or email?

Iggenix, Inc Questions

News

IgGenix Announces Completion of Enrollment for Phase 1 Clinical Trial "ACCELERATE Peanut" with IGNX001 in Peanut Allergy - Yahoo Finance

IgGenix Announces Completion of Enrollment for Phase 1 Clinical Trial "ACCELERATE Peanut" with IGNX001 in Peanut Allergy Yahoo Finance

RNA sequencing uncovers more than 60 monoclonal antibodies linked to alpha-gal syndrome - Healio

RNA sequencing uncovers more than 60 monoclonal antibodies linked to alpha-gal syndrome Healio

Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial - Healio

Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial Healio

IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial "ACCELERATE Peanut" Evaluating IGNX001 in Peanut Allergy - PR Newswire

IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial "ACCELERATE Peanut" Evaluating IGNX001 in Peanut Allergy PR Newswire

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy - Business Wire

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy Business Wire

IgGenix: engineering antibodies to fight food allergies - Nature

IgGenix: engineering antibodies to fight food allergies Nature

IgGenix sprints to clinic with peanut allergy candidate and additional $40M - Endpoints News

IgGenix sprints to clinic with peanut allergy candidate and additional $40M Endpoints News

IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch - PR Newswire

IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch PR Newswire

IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress - PR Newswire

IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress PR Newswire

Top Iggenix, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant